Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | S100B | P04271 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744331 | 0.82 | ALDH1A1 (0.50) | ALDH1A1ALOX15CYP3A4MAPK1TDP1 | |
| SCHEMBL11301670 | 0.78 | S100B (0.60) | ALDH1A1ALOX15CYP3A4MAPK1TDP1 | |
| SCHEMBL7692723 | 0.78 | ALDH1A1 (0.50) | ALDH1A1ALOX15CYP3A4MAPK1TDP1 | |
| SCHEMBL31361979 | 0.78 | ALDH1A1 (0.52) | ALDH1A1ALOX15CYP3A4MAPK1TDP1 | |
| SCHEMBL2313495 | 0.78 | ALDH1A1 (0.52) | ALDH1A1ALOX15CYP3A4MAPK1TDP1 | |
| SCHEMBL14115708 | 0.77 | SMN1; SMN2 (0.44) | ALDH1A1ALOX15MAPK1TP53HSD17B10 | |
| SCHEMBL2858939 | 0.77 | ALDH1A1 (0.35) | ALDH1A1CYP3A4MAPK1HSD17B10KMT2A | |
| SCHEMBL15935766 | 0.74 | MAPT (0.47) | ALDH1A1ALOX15CYP3A4MAPK1TDP1 | |
| SCHEMBL2367265 | 0.74 | APAF1 (0.56) | ALDH1A1ALOX15CYP3A4MAPK1TDP1 | |
| SCHEMBL29161898 | 0.73 | JAK3 (0.35) | ALDH1A1CYP3A4KCNH2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989173-B | Imidazole compound, pharmaceutical composition and application thereof | 广州市恒诺康医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2022184000-A1 | IMIDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-114989173-A | Imidazole compound, pharmaceutical composition and application thereof | 广州市恒诺康医药科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-2687507-B1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-9035059-B2 | Nitrogen-containing condensed heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| US-9035059-B2 | Nitrogen-containing condensed heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| WO-2014118092-A2 | DYE COMPOSITION COMPRISING AT LEAST ONE PARTICULAR LIPOPHILIC META-PHENYLENEDIAMINE COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES | L'OREAL (FR) | 2014-08-07 | — | — | WO | disclosed |
| EP-2687507-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-7566736-B2 | Substituted indoles, compositions containing them, method for the production thereof and their use | AVENTIS PHARMA S.A. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1841762-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006061493-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | IDO1, RB1, IDO2 | ALDH1A1 304/4885ALOX15 1271/4885CYP3A4 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.